Absence of Cyclooxygenase-2 Exacerbates Hypoxia-Induced Pulmonary Hypertension and Enhances Contractility of Vascular Smooth Muscle Cells

Laura E. Fredenburgh, MD; Olin D. Liang, PhD; Alvaro A. Macias, MD; Thomas R. Polte, PhD; Xiaoli Liu, MD, PhD; Dario F. Riascos, MD; Su Wol Chung, PhD; Scott L. Schissel, MD, PhD; Donald E. Ingber, MD, PhD; S. Alex Mitsialis, PhD; Stella Kourembanas, MD; Mark A. Perrella, MD

Background—Cyclooxygenase-2 (COX-2) is upregulated in pulmonary artery smooth muscle cells (PASMCs) during hypoxia and may play a protective role in the response of the lung to hypoxia. Selective COX-2 inhibition may have detrimental pulmonary vascular consequences during hypoxia.

Methods and Results—To investigate the role of COX-2 in the pulmonary vascular response to hypoxia, we subjected wild-type and COX-2–deficient mice to a model of chronic normobaric hypoxia. COX-2-null mice developed severe pulmonary hypertension with exaggerated elevation of right ventricular systolic pressure, significant right ventricular hypertrophy, and striking vascular remodeling after hypoxia. Pulmonary vascular remodeling in COX-2–deficient mice was characterized by PASMC hypertrophy but not increased proliferation. Furthermore, COX-2–deficient mice had significant upregulation of the endothelin-1 receptor (ETA) in the lung after hypoxia. Similarly, selective pharmacological inhibition of COX-2 in wild-type mice exacerbated hypoxia-induced pulmonary hypertension and resulted in PASMC hypertrophy and increased ETα receptor expression in pulmonary arterioles. The absence of COX-2 in vascular smooth muscle cells during hypoxia in vitro augmented traction forces and enhanced contractility of an extracellular matrix. Treatment of COX-2–deficient PASMCs with iloprost, a prostaglandin I2 analog, and prostaglandin E2 abrogated the potent contractile response to hypoxia and restored the wild-type phenotype.

Conclusions—Our findings reveal that hypoxia-induced pulmonary hypertension and vascular remodeling are exacerbated in the absence of COX-2 with enhanced ETA receptor expression and increased PASMC hypertrophy. COX-2–deficient PASMCs have a maladaptive response to hypoxia manifested by exaggerated contractility, which may be rescued by either COX-2–derived prostaglandin I2 or prostaglandin E2. (Circulation. 2008;117:2114-2122.)

Key Words: hypertension, pulmonary hypertrophy hypoxia prostaglandins remodeling vasculature

Pulmonary hypertension is a severe and frequently fatal disease commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease and interstitial lung disease.1,2 The hallmark of pulmonary hypertension is the development of elevated pulmonary vascular resistance, leading to increased right ventricular (RV) afterload and ultimately progression to right heart failure and death. The mechanisms by which low-resistance arterioles in the pulmonary circulation narrow include pulmonary vasoconstriction, in situ thrombosis, and pulmonary vascular remodeling.1 Vascular remodeling involves pathological changes in all 3 layers of the pulmonary arteries, including endothelial dysfunction, smooth muscle cell hyperplasia, and hypertrophy, as well as adventitial fibroblast proliferation, myofibroblast differentiation, and extracellular matrix deposition.3 Endothelial injury leads to the release of potent vasoconstrictors, including thromboxane A2 and endothelin-1 (ET-1), which can overwhelm the effects of endothelium-derived vasodilators such as prostacyclin (prostaglandin [PG] I2) and nitric oxide, thereby promoting remodeling of the arteriolar wall.1,3

Clinical Perspective p 2122

Although current state-of-the-art therapy with vasodilators, endothelin receptor antagonists, and phosphodiesterase inhibitors may stabilize disease and improve quality of life in patients with pulmonary hypertension,1,2 these agents do not reverse the underlying vascular remodeling process. There is
therefore a need to identify novel pathways and potential therapeutic targets that target vascular remodeling to halt or reverse the progression of this devastating disease.

The cyclooxygenase (COX) enzymes (COX-1 and COX-2), which catalyze conversion of arachidonic acid to a series of prostanoids, may play a key role in the development of pulmonary vascular remodeling in response to hypoxia. COX-2, the inducible isozyme of COX, is upregulated by hypoxia in pulmonary artery smooth muscle cells (PASMCs), and both elevated thromboxane A2 levels and reduced PGI2 levels have been demonstrated in patients with idiopathic and secondary forms of pulmonary hypertension.13–15 Overexpression of PGI2 synthase in the lung protects against the development of hypoxia-induced pulmonary hypertension in mice,6 and continuous administration of prostacyclin to patients with pulmonary arterial hypertension improves mortality and quality of life.7 Furthermore, deletion of the PGI2 receptor exacerbates vascular remodeling in a mouse model of hypobaric hypoxia–induced pulmonary hypertension.8 However, the role of COX-2 in hypoxia-induced pulmonary vascular remodeling has not yet been elucidated.

Recent studies have demonstrated accelerated atherosclerosis9,10 and vascular remodeling in mice lacking the PGI2 receptor.11 Deletion of the PGI2 receptor or selective COX-2 inhibition enhances vascular hyperplasia and remodeling of the systemic vasculature in murine models of transplant arteriosclerosis and flow-dependent vascular remodeling.11 In addition, recent work suggests that COX-2 inhibition enhances platelet deposition and intravascular thrombosis in a rat model of hypobaric hypoxia–induced pulmonary hypertension.12 Selective inhibition of COX-2 also is associated with an increased incidence of adverse cardiovascular events.13–15 These potential vascular sequelae associated with pharmacological COX-2 inhibition appear to arise from alterations in multiple vascular effectors, including PGI2 and PGE2, which may directly or indirectly modulate platelet function, vascular tone, and remodeling.15 Selective COX-2 inhibition may thus perturb the complex balance of vascular mediators and promote vascular remodeling and/or a prothrombotic state in susceptible patients.13–15

Given the potential consequences of COX-2 inhibition on the systemic vasculature, we examined the effect of COX-2 deficiency on the development of pulmonary hypertension and vascular remodeling in a mouse model of chronic hypoxia. Mice deficient in COX-2 developed an exaggerated response to hypoxia with elevated RV systolic pressure (RVSP), striking pulmonary vascular remodeling, and severe RV hypertrophy (RVH). Interestingly, the absence of COX-2 during hypoxia led to increased PASMC hypertrophy but did not enhance smooth muscle cell proliferation under hypoxic conditions either in vivo or in vitro. In addition, deficiency of COX-2 during hypoxia resulted in significant upregulation of the ET-1 receptor (ETa), increased traction forces, and augmented contractility of PASMCs on collagen gel matrices. This enhanced contractility was attenuated by both exogenous iloprost, a PGI2 analog, and PGE2. Our findings suggest that COX-2 plays a critical protective role in the pulmonary vasculature under hypoxic conditions and that selective COX-2 inhibition may be hazardous to patients with pulmonary hypertension, particularly under conditions of hypoxemia.

**Methods**

Detailed methods are described in the expanded Methods in the Data Supplement available online.

**Animals**

Mice that were wild type (WT) or homozygous null for targeted disruption of COX-2 (B6:129S7-Ptgs2tm1Jed, The Jackson Laboratory, Bar Harbor, Me) were studied.

**Hypoxic Exposure and Hemodynamic Measurements**

Eight- to 10-week-old COX-2+/− and COX-2−/− littermates were exposed to normobaric hypoxia (10% O2, OxyCycler chamber, Biospherix Ltd, Redfield, NY)16,17 or normoxia (21% O2) for 2 weeks. Eight- to 10-week-old C57BL/6 WT mice were treated with vehicle or nimesulide (40 mg/L)11,18 in the drinking water during a 2-week exposure to hypoxia or normoxia. After exposure, mice were anesthetized with sodium pentobarbital (60 mg/kg), and hemodynamic measurements were performed.17,19 The hearts were excised, and the ventricles were dissected and weighed. RVH was assessed by normalizing RV weight to total body weight (RV weight/total body weight).16,17

**Histological Analysis and Morphometry**

Lungs were inflated, harvested, fixed in methyl Carnoy’s solution, and embedded in paraffin. Sections were stained with hematoxylin and eosin20 and immunostained for α-smooth muscle actin (α-SMA; 1:50).21,22 Remodeling was quantified as described previously.16,17,19 Percent wall thickness was calculated as follows: wall thickness (%)=(area−area)/area×100, where area represents the external diameter and area represents the internal diameter of each vessel.16,17,19 PASMC hypertrophy was calculated as vessel wall area divided by nuclei per vessel and reported as area per cell.

**Western Blot Analysis**

Protein extracts from lungs exposed to hypoxia or normoxia were analyzed by Western blot analysis22–24 with a monoclonal α-SMA antibody (1:2000) and a monoclonal ETa antibody (1:500, BD Biosciences, San Jose, Calif). Equal loading was confirmed with an anti-tubulin antibody (1:8000).

**Cell Culture**

Primary aortic smooth muscle cells (VSMCs) were isolated from COX-2−/− and COX-2+/+ embryos at 18.5 days postconception as described.22,24 Primary PASMCs were isolated from adult (8- to 10-week-old) COX-2−/− and COX-2+/± mice as described with modification.25 Hypoxia experiments were performed in an InvoVo 400 Hypoxia Workstation (Biotrace International BioProducts, Bothell, Wash).26

**Traction Force Microscopy**

Contractile forces exerted by COX-2−/− and COX-2+/+ VSMCs were assessed by traction force microscopy as described.27–29 Cells were exposed to hypoxia (1%) or normoxia for 24 hours, and in certain experiments, cells were treated with ET-1 (20 nmol/L). Traction forces exerted by individual cells before and after ET-1 treatment were determined.

**Collagen Matrix Contraction Assay**

COX-2−/− and COX-2+/+ PASMCs and VSMCs were plated on type I collagen gel matrices and exposed to hypoxia or normoxia for 24 hours. Gel size was defined as the sum of the 2 longest gel diameters; gel contraction was expressed as a percentage of the original gel size.30,31 In certain experiments, cells were treated with PGE2 (1 μmol/L), iloprost (1 μmol/L), or vehicle (30% ethanol in PBS) during hypoxic exposure. In other experiments, cells were treated
with either forskolin (10 μmol/L) or vehicle (4% ethanol in DMEM) during hypoxic exposure. Rat pulmonary artery smooth muscle (RPASMCs) were treated with NS-398 (5 μmol/L) or vehicle (25% dimethyl sulfoxide in PBS).

**Statistical Analysis**

Data are presented as mean±SEM. Statistical significance was determined by the Student t test for comparisons between 2 groups; ANOVA was used for comparisons between ≥2 groups or for multiple comparisons. Statistical significance was accepted at P<0.05.

The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

**Results**

**Absence of COX-2 Leads to Exaggerated Elevation of RVSP and Severe RVH After Chronic Hypoxia**

To determine the role of COX-2 in the pulmonary vascular response to hypoxia, COX-2−/− and COX-2+/+ mice were exposed to 2 weeks of normobaric hypoxia or normoxia. COX-2 was induced 5-fold in the lungs of WT mice after hypoxia with no difference in COX-1 expression between COX-2−/− and COX-2+/+ mice either at baseline or after exposure to hypoxia (Figure 1 of the online Data Supplement). COX-2−/− mice developed significant elevation in RVSP (31.3±1.3 mm Hg) compared with COX-2+/+ mice (25.7±1.5 mm Hg; P<0.05) and normoxic controls (Figure 1A). In addition, COX-2−/− mice developed significant RVH (RV weight/body weight, 1.08±0.04 mg/g) compared with COX-2+/+ mice (0.88±0.05 mg/g; P<0.05) and normoxic controls (Figure 1B). Total body weight was not different between COX-2−/− (24.1±0.6 g) and COX-2+/+ (23.5±0.45 g) mice.

In addition, WT mice were treated with nimesulide, a selective COX-2 inhibitor, during exposure to hypoxia compared with normoxia. Similar to COX-2−/− mice, nimesulide-treated WT mice developed more severe pulmonary hypertension after exposure to hypoxia with a significant increase in RVSP (26±1 mm Hg) compared with vehicle-treated WT mice (22±1.3 mm Hg; P<0.05) and normoxic controls. In addition, nimesulide-treated WT mice developed exaggerated RVH in response to hypoxia with a significant percentage increase in RV weight (33%; P<0.05) compared with vehicle-treated WT mice.

**Absence of COX-2 Leads to Enhanced Pulmonary Vascular Remodeling After Chronic Hypoxia**

Hematoxylin and eosin staining revealed enhanced vascular remodeling in COX-2−/− mice after hypoxia compared with COX-2+/+ mice (Figure 2A). COX-2−/− mice developed exaggerated vascular remodeling with a significant increase in wall thickness of pulmonary arterioles (51±2.4%) after hypoxia compared with COX-2+/+ mice (33.7±2.6%; P<0.05) and normoxic controls (Figure 2B). Similarly, nimesulide-treated WT mice developed enhanced vascular remodeling after exposure to hypoxia with a significant increase in pulmonary arteriolar wall thickness (43±1%) compared with vehicle-treated WT mice (33.5±1.1%; P<0.05) and normoxic controls (Figure 2C).

**Neither Proliferation nor Migration Differ Between COX-2−/− and COX-2+/+ VSMCs Exposed to Hypoxia**

To elucidate the mechanisms by which COX-2 modulates pulmonary vascular remodeling, we investigated the effect of COX-2 deficiency on VSMC proliferation and migration. As shown in supplemental Figure II, during exposure to hypoxia, neither proliferation nor migration differed between COX-2−/− and COX-2+/+ VSMCs in response to platelet-derived growth factor. In addition, BrdU staining demonstrated no difference in proliferation in vivo between COX-2−/− and COX-2+/+ mice after hypoxia (data not shown); however, there was a clear increase in the number of BrdU-positive cells in the pulmonary vessels of both hypoxic groups compared with baseline. These results demonstrate that neither enhanced VSMC proliferation nor migration accounts for the hypoxic vascular remodeling in COX-2−/− mice.

**COX-2−/− Mice Have Enhanced PASMC Hypertrophy After Hypoxia**

Trichrome staining revealed minimal collagen deposition in the distal remodeled vessels with no difference between COX-2−/−
and COX-2−/− mice (data not shown). However, immunostaining for α-SMA demonstrated that, after hypoxia, COX-2−/− mice developed striking vascular remodeling with neomuscularization of distal pulmonary arterioles, characterized by large neointimas containing α-SMA-positive cells (Figure 3A). In contrast, COX-2+/+ mice developed significantly less remodeling with few α-SMA-positive cells in remodeled vessels. To
quantify α-SMA in the lungs of COX-2−/− and COX-2+/+ mice after hypoxia and normoxia, Western blot analysis was performed for α-SMA. When corrected for loading, there was no difference in α-SMA protein expression between COX-2−/− and COX-2+/+ mice at baseline. However, after hypoxia, lungs of COX-2−/− mice demonstrated a nearly 3-fold increase in α-SMA protein expression compared with only a 1.3-fold increase in lungs of COX-2+/+ mice (Figure 3B).

These findings, in addition to our proliferation and migration results, suggested that smooth muscle cell hypertrophy may be the predominant mechanism driving hypoxic vascular remodeling in lungs of COX-2−/− mice. Indeed, morphometric analysis demonstrated that COX-2−/− mice developed significant PASMC hypertrophy after hypoxia with a significant increase in area per cell (1693±266 pixels) compared with COX-2+/+ mice (678±41 pixels; *P<0.05; Figure 3C). Similarly, nimesulide-treated WT mice developed exaggerated PASMC hypertrophy after exposure to hypoxia with a significant increase in area per cell (1405±62 pixels) compared with vehicle-treated WT mice (686±30 pixels; *P<0.05) and normoxic controls (supplemental Figure III).

**COX-2−/− VSMCs Have Enhanced Traction Forces After Hypoxia**

Previous studies with cultured pulmonary VSMCs have shown that myosin light chain phosphorylation and cell contractility increase in parallel with cell area as the cells spread on the extracellular matrix.29 Thus, to determine whether a difference in VSMC contractility may contribute to the exaggerated pulmonary hypertension and vascular remodeling in COX-2−/− mice, we used traction force microscopy to measure the traction forces exerted by individual VSMCs after exposure to hypoxia in vitro (Figure 4A). COX-2−/− and COX-2+/+ VSMCs had no difference in traction forces under normoxic conditions (COX-2−/−, 102±14 Pa; COX-2+/+, 108±19 Pa); however, after hypoxia, COX-2−/− VSMCs developed a significant increase in traction forces (150±18 Pa) compared with COX-2+/+ VSMCs (104±14 Pa; *P<0.05; Figure 4B). These data suggest that deficiency of COX-2 during hypoxia dramatically alters the contractile response of individual VSMCs.

**Absence of COX-2 During Hypoxia Leads to Enhanced ETα Receptor Expression and Exaggerated Traction Forces in Response to ET-1**

To investigate the mechanism by which deficiency of COX-2 augments the contractility of VSMCs during hypoxia, we harvested protein from lungs of COX-2−/− and COX-2+/+ mice and performed Western blot analysis for the ETα receptor. COX-2−/− mice had dramatic induction of the ETα receptor after hypoxia with a 5-fold induction in ETα receptor protein expression compared with only a 5% increase in COX-2+/+ mice (Figure 5A). In addition, after exposure to hypoxia, nimesulide-treated WT mice demonstrated a >30-fold increase in ETα receptor expression in pulmonary arterioles by immunohistochemistry compared with only a 3-fold increase in vehicle-treated WT mice (supplemental Figure IV). Furthermore, when COX-2+/+ and COX-2−/− VSMCs were treated with ET-1 after hypoxia, COX-2−/− VSMCs developed a significant increase in traction forces (202±17 Pa) compared with COX-2+/+ VSMCs (160±15 Pa; *P<0.05) and normoxic controls (Figure 5B).
COX-2−/− PASMCs Have Enhanced Contractility on Collagen Gels After Hypoxia

Given these findings, we investigated whether COX-2−/− PASMCs would demonstrate enhanced contractility of a 3-dimensional collagen matrix. Consistent with our traction force microscopy results, COX-2−/− PASMCs demonstrated enhanced contraction of collagen matrixes after hypoxia (Figure 6A) compared with COX-2+/+ PASMCs. At 4 hours after matrix release, hypoxic COX-2−/− PASMCs exhibited exaggerated gel contraction (55±2.2% of original gel size) compared with hypoxic COX-2+/+ PASMCs (80±2.3% of original gel size; P<0.05; Figure 6B). Similarly, COX-2−/− VSMCs demonstrated exaggerated gel contraction (48±1.9% of original gel size) compared with COX-2+/+ VSMCs (73±5% of original gel size; P<0.05) after hypoxic exposure (Figure 6B). In addition, pharmacological inhibition of COX-2 in an RPASMC cell line resulted in increased contraction (67±3.4% of original gel size) during hypoxia compared with vehicle control (83±1.6% of original gel size; P<0.05; Figure 6B).

Iloprost and PGE2 Attenuate Enhanced Contractility of COX-2−/− PASMCs on Collagen Gels After Hypoxia

To determine whether the administration of prostanoids could rescue COX-2−/− PASMCs from this enhanced contractile response during hypoxia, we first analyzed the abundance and relative contribution of COX-2−/− PASMCs and VSMCs were exposed to hypoxia for 24 hours, and supernatants were ana-
alyzed for PGE$_2$ and 6-keto-PGF$_{1α}$, a stable PGI$_2$ metabolite. Levels of PGE$_2$ were significantly higher in WT VSMCs compared with WT PASMCs after hypoxia. In addition, 6-keto-PGF$_{1α}$ was as abundant as PGE$_2$ in WT VSMCs after hypoxia but almost 8-fold more abundant than PGE$_2$ in hypoxia-exposed WT PASMCs (supplemental Figure V). As expected, PGE$_2$ and 6-keto-PGF$_{1α}$ levels were markedly lower in COX-2–/– PASMCs and VSMCs.

To investigate whether repletion of these COX-2–derived prostanoids would alter the contractile phenotype of COX-2–/– PASMCs and VSMCs during hypoxia, we performed collagen matrix contraction assays in the presence of exogenous PGE$_2$ or iloprost, a PGI$_2$ analog. Vehicle-treated COX-2–/– PASMCs and VSMCs demonstrated exaggerated gel contraction after hypoxia compared with WT controls. Contraction by hypoxic COX-2–/– PASMCs was significantly attenuated by either iloprost (84 ± 2.6% of original gel size; P < 0.05) or PGE$_2$ (81 ± 2.3% of original gel size; P < 0.05; Figure 7A). However, exaggerated contraction by COX-2–/– VSMCs was attenuated only by PGE$_2$ (79 ± 2.4% of original gel size; P < 0.05), not iloprost (61 ± 2.7% of original gel size; Figure 7B). In addition, to determine whether rescue of this phenotype is cAMP mediated, we performed collagen contraction assays in the presence of forskolin, an activator of adenylate cyclase. Similar to PGE$_2$, forskolin attenuated contraction of both COX-2–/– PASMCs and VSMCs after exposure to hypoxia (supplemental Figure VI).

**Discussion**

This study highlights 3 important new concepts. First, deficiency or pharmacological inhibition of COX-2 is detrimental during exposure to hypoxia, leading to exacerbation of pulmonary hypertension, accelerated vascular remodeling characterized by PASMC hypertrophy, and significant up-regulation of the ETA receptor. Second, deficiency of COX-2 in VSMCs during hypoxia enhances contractile forces both at a cellular level and in their interactions with the extracellular matrix. Third, repletion of either COX-2–derived PGI$_2$ or PGE$_2$ to COX-2–/– PASMCs attenuates their potent contractility in response to hypoxia, thus restoring the WT phenotype.

In this study, we examined the role of COX-2 in pulmonary vascular remodeling using a murine model of chronic hypoxia-induced pulmonary hypertension. COX-2 is upregulated in PASMCs under hypoxic conditions, and our data provide evidence that it plays a protective role in response to hypoxia. Pharmacological inhibition of COX-2 is associated with remodeling of the systemic vasculature in murine models; however, the effect of COX-2 deficiency on the pulmonary vasculature, particularly under conditions of hypoxemia, has not been fully defined. Recent work by Pidgeon et al. suggests that pharmacological inhibition of COX-2 in a rat model of hypobaric hypoxia enhances platelet activation and intravascular thrombosis, which were partially attenuated by a thromboxane receptor antagonist. However, the effect of COX-2 deficiency on remodeling and contractility of PASMCs in response to hypoxia has not yet been elucidated.

Our findings illustrate that COX-2–deficient mice develop severe pulmonary hypertension characterized by exaggerated elevation of RVSP, significant RVH, and striking vascular remodeling after only 2 weeks of hypoxia. In contrast, WT mice develop less severe pulmonary hypertension and minimal vascular remodeling in response to 2 weeks of hypoxia. In addition, selective pharmacological COX-2 inhibition during exposure to chronic hypoxia led to an exaggerated response to hypoxia, similar to COX-2–null mice, with severe pulmonary hypertension and profound pulmonary vascular remodeling compared with vehicle-treated controls. We observed the same extent of cellular proliferation in COX-2–/– and COX-2–/– mice after hypoxia, but COX-2–/– mice developed significant PASMC hypertrophy, accounting for the dramatic vascular remodeling. Our findings suggest that this enhanced hypertrophic response of the pulmonary vasculature to hypoxia in COX-2–null mice may be due in part to enhanced expression of the ETA receptor during hypoxia because ET-1 has been linked to VSMC hypertrophy. Interestingly, although PGI$_2$ has been shown to have inhibi-
tory effects on the proliferation of human PASMCs. Our data demonstrate that genetic deficiency of COX-2 does not alter the proliferative response of the pulmonary arteriolar vasculature to hypoxia but rather promotes a hypertrophic remodeling response.

In addition to vascular remodeling, pulmonary vascular resistance may increase as a result of intravascular thrombosis after chronic hypoxia. We did not observe significant intravascular thrombosis in our mouse model, as had been previously observed in a rat model of hypobaric hypoxia–induced pulmonary hypertension. Our findings now provide evidence that, in addition to vascular thrombosis, COX-2 deficiency results in enhanced vascular remodeling, which exacerbates the rise in pulmonary vascular resistance in response to hypoxia.

The present study also extends our understanding of how chronic hypoxia alters PASMC contractility at a cellular level. We have demonstrated that the absence of COX-2 during hypoxia enhances traction forces generated in individual VSMCs and augments contractility of PASMCs on an extracellular matrix. Previous work has illustrated a direct correlation between cellular traction forces and myosin light chain phosphorylation in PASMCs under normoxic conditions. Because myosin light chain phosphorylation and cell contractility have been shown to increase as cells enlarge by spreading on an extracellular matrix, our findings suggest that hypertrophy may explain the increased contractility of COX-2–deficient PASMCs under hypoxic conditions. Up-regulation of the ET\(_{A}\) receptor in COX-2–null mice during hypoxia likely accounts for this enhanced contractile phenotype during hypoxia, as we found an exaggerated contractile response to ET-1 in COX-2–deficient VSMCs. These findings expand on prior work demonstrating that prostacyclin analogs can inhibit ET-1 release in human PASMCs and that intravenous prostacyclin may either increase ET-1 clearance or decrease its release in patients with idiopathic pulmonary hypertension. Furthermore, we have shown that this phenotype can be reversed with exogenous iloprost and, interestingly, PGE2 treatment. Although attenuation of contractility with PGI2 was selective for PASMCs, both PGE2 and forskolin, an activator of adenylate cyclase, rescued the contractile phenotype in COX-2–null PASMCs and VSMCs, suggesting a cAMP-dependent mechanism.

Taken together, our results demonstrate that under hypoxic conditions, COX-2–deficient PASMCs have an enhanced hypertrophic and contractile response to ET-1 resulting in part from upregulation of the ET\(_{A}\) receptor. Our findings suggest that COX-2 induction during hypoxia attenuates expression of the ET\(_{A}\) receptor through a cAMP-dependent signaling pathway, thereby modulating the contractile and growth-promoting effects of ET-1. We cannot, however, exclude other potential mechanisms of enhanced contractility that COX-2 may modulate. For example, both acute and chronic hypoxia may regulate activity or expression of voltage-gated potassium (Kv) channels, which could alter Ca\(^{2+}\) influx and activate myosin light chain kinase. Potential downstream signaling mechanisms by which COX-2 may modulate ET\(_{A}\) receptor expression and mediate protection against hypoxia-induced pulmonary vascular remodeling include the protein kinase A and the exchange protein directly activated by cAMP (Epac)\(^{39}\) signaling pathways and will be the subject of future investigations.

**Conclusions**

Our findings have revealed a novel role for COX-2 in mediating protection against hypoxia-induced pulmonary hypertension and vascular remodeling, as well as modulating PASMC contractility. Pharmacological inhibition of COX-2 with selective COX-2 inhibitors has received significant attention in the literature recently. We now report that, in addition to well-recognized prothrombotic cardiovascular risks, selective COX-2 inhibition may have detrimental pulmonary vascular consequences. These findings may have significant clinical implications in patients with hypoxic lung diseases or preexisting pulmonary hypertension.

**Acknowledgments**

We thank Drs Rebecca M. Baron, Matthew D. Layne, Shaw-Fang Yet, and Bruce D. Levy for helpful comments and suggestions; Dr Jiao Wei and Bonna Ith for technical assistance; and Dr Stephen R. Walsh for careful review of the manuscript.

**Sources of Funding**

This work was supported by a Parker B. Francis Fellowship (Dr Fredenburgh), an American Lung Association Biomedical Research Grant (Dr Fredenburgh), as well as grants from the National Institute of General Medical Sciences including K08 GM083207 (Dr Fredenburgh) and R01 GM053249 (Dr Perrella) and grants from the National Heart, Lung, and Blood Institute, including T32 HL0007633 (Dr Fredenburgh), P50 HL67669 (Drs Ingber, Mitsialis, and Kourembanas), R01 HL55454 (Dr Kourembanas), and R01 HL60788 (Dr Perrella).

**Disclosures**

None.

**References**

Pulmonary hypertension is a severe disease commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease and interstitial lung disease. It is characterized by the development of pulmonary vascular remodeling, leading to elevated pulmonary vascular resistance and ultimately progression to right ventricular dysfunction and often death. Despite state-of-the-art therapy, morbidity and mortality rates remain high as a result of irreversible vascular remodeling. Pulmonary artery smooth muscle cell hypertrophy and significant upregulation of the endothelin-1 (ETA) receptor contribute to pulmonary hypertension.

COX-2, a key player in inflammatory processes, is upregulated in pulmonary artery smooth muscle cells under hypoxia and may play a protective role in the vascular response to hypoxia. However, exogenous COX-2 inhibition or pharmacological inhibition of COX-2 may exacerbate pulmonary hypertension. The absence or pharmacological inhibition of COX-2 leads to severe pulmonary hypertension. This finding suggests that selective COX-2 inhibition may have detrimental pulmonary vascular consequences in patients with hypoxic lung diseases or preexisting pulmonary hypertension.

Selective COX-2 inhibitors might worsen symptoms in patients with pulmonary hypertension.

**Clinical Perspective**

Pulmonary hypertension is a severe disease commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease and interstitial lung disease. It is characterized by the development of pulmonary vascular remodeling, leading to elevated pulmonary vascular resistance and ultimately progression to right ventricular dysfunction and often death. Despite state-of-the-art therapy, morbidity and mortality rates remain high as a result of irreversible vascular remodeling. Cyclooxygenase-2 (COX-2) is upregulated in pulmonary artery smooth muscle cells under hypoxia and may play a protective role in the vascular response to hypoxia. In the present study, we investigated the role of COX-2 in a mouse model of hypoxia-induced pulmonary hypertension. The absence of COX-2 or pharmacological inhibition of COX-2 led to severe pulmonary hypertension after hypoxia with exaggerated elevation of right ventricular systolic pressure, significant right ventricular hypertrophy, and striking vascular remodeling. Vascular remodeling was characterized by pulmonary artery smooth muscle cell hypertrophy and significant upregulation of the endothelin-1 (ET\(_A\)) receptor in the lung during hypoxia. Our findings also demonstrate that COX-2-deficient pulmonary artery smooth muscle cells have enhanced contractility after exposure to hypoxia that can be rescued by COX-2-derived prostaglandin E\(_2\) or prostaglandin I\(_2\). The results of our study suggest that COX-2 plays an important protective role in the lung under hypoxic conditions and that selective COX-2 inhibition may have detrimental pulmonary vascular consequences in patients with hypoxic lung diseases or preexisting pulmonary hypertension. These findings have significant clinical implications and raise the possibility that selective COX-2 inhibitors might worsen symptoms in patients with pulmonary hypertension.
Absence of Cyclooxygenase-2 Exacerbates Hypoxia-Induced Pulmonary Hypertension and Enhances Contractility of Vascular Smooth Muscle Cells
Laura E. Fredenburgh, Olin D. Liang, Alvaro A. Macias, Thomas R. Polte, Xiaoli Liu, Dario F. Riascos, Su Wol Chung, Scott L. Schissel, Donald E. Ingber, S. Alex Mitsialis, Stella Kourembanas and Mark A. Perrella

_Circulation_. 2008;117:2114-2122; originally published online April 7, 2008; doi: 10.1161/CIRCULATIONAHA.107.716241

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/117/16/2114

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/